Following a treat-to-target strategy resulted in remission at 24 months regardless of which of three different treatment plans (DMARD alone, DMARD plus prednisolone or DMARD plus etanercept) was used in a randomized, single-blinded study of 94 DMARD-naive patients with juvenile idiopathic arthritis (JIA). When averaged across the three groups, at 24 months 71% of patients had achieved inactive disease and 39% of patients had achieved drug-free inactive disease. Time-to-flare following DMARD discontinuation did not differ between the groups.